Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AR | P10275 | 3/20 | 0.32 |
| ▸ | CES2 | O00748 | 1/20 | 0.30 |
| ▸ | CES1 | P23141 | 1/20 | 0.30 |
| ▸ | KCNQ3 | O43525 | 1/20 | 0.30 |
| ▸ | KCNQ2 | O43526 | 1/20 | 0.30 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.30 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.30 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2883274 | 1.00 | AR (0.32) | ARCES2CES1KCNQ3KCNQ2 | |
| SCHEMBL2882432 | 1.00 | AR (0.32) | ARCES2CES1KCNQ3KCNQ2 | |
| SCHEMBL2884930 | 0.81 | AR (0.36) | ARCES2CES1KCNQ3KCNQ2 | |
| SCHEMBL2884932 | 0.81 | AR (0.36) | ARCES2CES1KCNQ3KCNQ2 | |
| SCHEMBL2882494 | 0.74 | CES2 (0.43) | CES2CES1KCNQ3KCNQ2 | |
| SCHEMBL2880794 | 0.70 | MCHR1 (0.40) | KCNH2MCHR1 | |
| SCHEMBL12975763 | 0.62 | MCHR1 (0.47) | CES2CES1KCNQ3KCNQ2KCNH2 | |
| SCHEMBL30255116 | 0.61 | CES2 (0.47) | CES2CES1 | |
| SCHEMBL27902046 | 0.61 | CES2 (0.47) | CES2CES1 | |
| SCHEMBL27899922 | 0.61 | CES2 (0.47) | CES2CES1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100324049-A1 | DIARYL KETIMINE DERIVATIVE HAVING ANTAGONISM AGAINST MELANIN-CONCENTRATING HORMONE RECEPTOR | MSD K.K. (JP) | 2010-12-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100324049-A1 | DIARYL KETIMINE DERIVATIVE HAVING ANTAGONISM AGAINST MELANIN-CONCENTRATING HORMONE RECEPTOR | MC1R, MCHR1, MCHR2 | AR 47/4885CES2 2828/4885CES1 1529/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.